ExThera Completes Phase I OSCAR I Trial
ExThera Medical has successfully completed the Phase I OSCAR I Study at OU Health Stephenson Cancer Center, affiliated with the University of Oklahoma. The OSCAR I Study is a prospective,…
Category Pharma/Biotech
Read MoreExThera Completes Phase I OSCAR I Trial
C2N Secures Funding to Develop Decentralized Mass Spectrometry for Global Alzheimer’s Testing
C2N Diagnostics, a global leader in Alzheimer’s diagnostics with its Precivity blood tests, plans to develop a fully automated and standardized high-resolution LC-MS platform. This technology will allow local clinical…
Almirall Showcases New Biologics Data for Psoriasis and Atopic Dermatitis at EADV Congress, Celebrating 80 Years of Innovation
Almirall, S.A. (ALM), a global leader in medical dermatology, will participate in the 33rd Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam from September 25 to…
Final Overall Survival Results of Datopotamab Deruxtecan in Metastatic HR Positive, HER2 Low/Negative Breast Cancer: TROPION-Breast01 Phase 3 Trial
Topline Results from TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan The TROPION-Breast01 phase 3 trial evaluating datopotamab deruxtecan (Dato-DXd) against investigator’s choice chemotherapy has reported that while the treatment met…
Alzprotect Reports Positive Results from Phase 2a PSP Study Extension
Alzprotect, a French biopharma company, has successfully completed the open-label extension (OLE) phase of its Phase 2a trial for AZP2006 (ezeprogind®) in treating Progressive Supranuclear Palsy (PSP). Results from the…
MedTech Innovator Chosen to Lead BARDA Accelerator Hub
MedTech Innovator (MTI), the world’s largest accelerator for medical technology companies, announced that its BioTools Innovator (BTI) program has been chosen as the Enabling Technologies Hub for the next generation…
Novotech Appoints Dr. Yooni Kim as Managing Director for Asia Pacific
Novotech, an international contract research organization (CRO), has announced the appointment of Dr. Yooni Kim as Managing Director of the Asia Pacific (APAC) region, effective September 1, 2024. This strategic…
RevBio Secures $2.4M NIH Grant for Bone Adhesive Trial, Enrolls First 5 Patients
RevBio, Inc. has secured a $2.4 million Phase II SBIR grant from the National Institute of Neurological Disease and Stroke (NINDS), part of the NIH. The two-year grant will support…
Japan Approves CSL and Arcturus’ Updated mRNA COVID-19 Vaccine for JN.1 Strain
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®. The new vaccine…
FDA Approves Ocrevus Zunovo™: First Twice-Yearly 10-Minute Injection for MS
Genentech, part of the Roche Group, announced that the U.S. FDA has approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq) for treating relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).…
Viridian Therapeutics Prices Upsized Public Offering of Common and Preferred Stock
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotech firm specializing in developing treatments for rare and serious diseases, has announced the pricing of its public offering. The company will sell 10,666,600…
Cellworks Biosimulation Pinpoints NSCLC Patients for Chemo-Immunotherapy Combo
Cellworks Group Inc., a leader in personalized therapy decision support and precision drug development, recently announced the results of a study demonstrating the accuracy of its biosimulation platform in predicting…